The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2009Testing PDE-1 Inhibitor in MPTP-treated Macaques
Promising Outcomes of Original Grant:
Our goal is to develop novel therapeutic molecules that promote normal dopamine neurotransmission in the brain affected by PD. We hypothesize that these molecules... -
Rapid Response Innovation Awards, 2009Effect of novel sirtuin inhibitors on alpha-synuclein toxicity in a Parkinson disease pre-clinical model
Objective/Rationale:
The objective of the proposed research is to test the ability of novel sirtuin inhibitors to protect against dopamine neuron toxicity in a pre-clinical model of Parkinson's... -
Rapid Response Innovation Awards, 2009Rational Vectors For PD
Objective/Rationale:
The project is hot on the trail of key suspect players in Parkinson’s disease. The output of an innovative screening process put forth a handful of candidate enzymes in a lower... -
Rapid Response Innovation Awards, 2009From Anti-aggregation Assay to Treatment for Parkinson's Disease: Developing a Secondary Screen to Bridge High throughput Screen and Cellular Assay
Objective/Rationale:
We want to develop a series of secondary assays that will allow us to shortlist likely drug candidates for therapy against Parkinson’s disease. These assays will bridge the gap... -
Rapid Response Innovation Awards, 2009Investigating the Potential effect of Peroxisome Proliferation in Diminishing Alpha-synuclein Pathogenesis
Objective/Rationale:
Alpha-synuclein is a protein critically involved in the pathogenesis of Parkinson’s disease. Growing evidence link alpha-synuclein pathogenesis in PD and brain lipid metabolism... -
Rapid Response Innovation Awards, 2009Crystal Structure of Alpha-Synuclein; Toward Rational Drug Design
Objective/Rationale: The alpha-synuclein is implicated in the pathogenesis of Parkinson’s disease. An aggregated form of synuclein containing many molecules has been proposed to interact destructively...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.